US Supreme Court rebuffs pharma challenge to Biden-era drug price

The U.S. Supreme Court declined to hear a pharmaceutical industry challenge to Medicare drug-price controls adopted under the Biden administration. The ruling leaves the discount framework in place, which drugmakers say pressures pricing and could weigh on innovation. The decision is a modest negative for large pharma and a supportive signal for Medicare cost containment.

Analysis

The U.S. Supreme Court declined to hear a pharmaceutical industry challenge to Medicare drug-price controls adopted under the Biden administration. The ruling leaves the discount framework in place, which drugmakers say pressures pricing and could weigh on innovation. The decision is a modest negative for large pharma and a supportive signal for Medicare cost containment.